Sponsored Links
| Additional Results From A Phase 2b Study Of Lesinurad In Combination With Allopurinol |
 |
 |
 |
| Medical News - Gout | |||
|
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK... Read more: Gout News From Medical News Today
|